Evidence map›Paper›PMID 41333023›Full record

ReviewFrontiers in pharmacology2025

An overview of the mechanistic approaches of antifungal nanomaterials.

Sarmistha Saha, Nadezhda Sachivkina, Regina Gurina, Ekaterina Neborak, Natallia Zhabo, Marina Avdonina, Maria Molchanova

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarmistha SahaDepartment of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura, Uttar Pradesh, India.
Nadezhda SachivkinaDepartment of Microbiology V.S. Kiktenko, Institute of Medicine, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow, Russia.
Regina GurinaAgrarian and Technological Institute, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow, Russia.
Ekaterina NeborakDepartment of Biochemistry T.T. Berezov, Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), Moscow, Russia.
Natallia ZhaboDepartment of Foreign Languages, Institute of Medicine, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow, Russia.
Marina AvdoninaDepartment of Linguistics and Intercultural Communication, Moscow State Linguistic University, Moscow, Russia.
Maria MolchanovaDepartment of Foreign Languages, Institute of Medicine, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antifungal medications currently available on the market have significant drawbacks, including serious side effects and poor absorption. Nanotechnology offers a promising solution to address these issues. Metal nanoparticles, polymer nanoparticles, dendrimers, liposomes, and carbon quantum dots are often employed nano-delivery systems in antifungal therapy. While nanotechnology has several benefits, including improved oral bioavailability, less side effects, controlled release, and targeted delivery, it also has significant drawbacks. We reviewed the limitations of current commercial antifungal solutions, the primary mechanistic insights by which nanotechnology can enhance antifungal efficacy, and the challenges associated with these approaches. For optimum therapeutic interventions, modifying the surfaces of nanomaterials could be considered to improve their interaction with fungal cells. This can be achieved through targeted delivery to the fungal cell wall and membrane or by utilizing electrostatic interactions, which allow nanoparticles to effectively adhere to fungal cells. Additionally, custom-designed nanomaterials can overcome challenges posed by physiological barriers such as the blood-brain barrier, corneal barrier, and skin barrier. Despite the challenges of implementing nanotechnology in antifungal treatments, its potential and innovative applications open up new possibilities for effective antifungal therapies in the future.

Indexed as

antibioticsantifungalantimicrobial resistanceCandida speciesnanotechnology

Identifiers

PMID41333023
PMCPMC12665767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.